In adults with newly diagnosed hyperuricemia but no established cardiometabolic disease, initiating urate-lowering therapy was associated with increased risk of composite cardiometabolic outcomes (HR 1.18) and all-cause mortality (HR 1.52) over a median follow-up of 3.03 years.
ULT initiation was associated with increased risk of the composite cardiometabolic outcome in adults without established cardiometabolic disease.
ULT initiation was associated with increased all-cause mortality in this population.
The increased cardiometabolic risk associated with ULT was evident among men.
Individuals without prior gout who initiated ULT showed increased cardiometabolic risk.
Users of xanthine oxidase inhibitors showed increased cardiometabolic risk associated with ULT.
Patients who achieved target serum urate levels below 5 mg/dL within 6 months showed increased cardiometabolic risk.
The study authors propose that serum urate may have context-dependent physiological roles in early metabolic states.
The study used a retrospective cohort design with propensity score matching from the TriNetX real-world database.
This research suggests that starting uric acid-lowering medications (such as allopurinol or febuxostat) in people who have high uric acid levels but no established heart disease, diabetes, or other metabolic conditions may actually increase their risk of developing heart and metabolic problems, and may increase their risk of dying from any cause. The study followed nearly 6,000 carefully matched adults for a median of about three years and found that those who started treatment had an 18% higher risk of a combined heart and metabolic disease outcome and a 52% higher risk of death compared to similar untreated individuals. The increased risk was particularly notable in men, in people who had never been diagnosed with gout, in those taking xanthine oxidase inhibitors (the most common type of uric acid-lowering drug), and in those whose uric acid levels dropped most aggressively—below 5 mg/dL within the first six months. This pattern suggests that the timing and context of treatment may matter greatly, and that not everyone with elevated uric acid may benefit from early pharmacological treatment. This research matters because uric acid-lowering drugs are increasingly being considered for people with high uric acid levels even before they develop gout or obvious organ damage. These findings raise the possibility that uric acid may play a protective biological role in people who do not yet have established metabolic disease, and that reducing it prematurely could be harmful. The study has limitations inherent to its observational design, including potential unmeasured confounding, so these findings should be interpreted cautiously and do not establish causation—but they do highlight an important question that the authors say warrants further research before broadening treatment recommendations.
Huo A, Wang S, Leong P, Wei J, Hsu T. (2026). Early urate-lowering therapy and cardiometabolic risk in adults without documented major cardiometabolic disease: a real-world cohort study.. Frontiers in endocrinology. https://doi.org/10.3389/fendo.2026.1934688